You just read:

AbbVie's Upadacitinib Shows Positive Results as Monotherapy in Phase 3 Rheumatoid Arthritis Study, Meeting All Primary and Key Secondary Endpoints

News provided by

AbbVie

Dec 20, 2017, 07:00 ET